The effect of the physical form of poly(lactic-co-glycolic acid) carriers on the humoral immune response to co-delivered antigen

被引:75
作者
Bennewitz, NL
Babensee, JE
机构
[1] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Georgia Tech, Emory Ctr Engn Living Tissues, Atlanta, GA 30332 USA
[2] Emory Univ, Atlanta, GA 30332 USA
基金
美国国家科学基金会;
关键词
poly (lactic-co-glycolic acid) microparticles and scaffolds; adjuvant; immune response; controlled release; tissue engineering;
D O I
10.1016/j.biomaterials.2004.08.023
中图分类号
R318 [生物医学工程];
学科分类号
0831 [生物医学工程];
摘要
A model shed antigen, ovalbumin (OVA), was incorporated into polymeric biomaterial carriers made of poly(lactic-co-glycolic acid) (PLGA) in the form of microparticles (MP) or scaffolds (SC). These polymeric biomaterial carrier vehicles with incorporated antigen were then injected or implanted into mice and the resulting time-dependent systemic humoral immune response towards the controlled released OVA was assessed by following the OVA-specific IgG concentration and isotypes using ELISA. To assess the differential level of enhancement of the immune response depending on the form of carrier vehicle (MP vs. SC), the total amount of polymer and OVA delivered was kept constant as well as the release rate of OVA for both carrier vehicles. The level of the humoral immune response was higher and sustained for OVA released from PLGA SC which were implanted with associated tissue damage, and lower and transient when the same amount of polymer and OVA were delivered from PLGA MP, which were minimally invasively delivered by injection. This immune response was primarily Th2 helper T cell-dependent, although for the strong adjuvant, CFA, and PLGA SC carriers there was both a Th2 and Th1 response contribution. These results implicate 'danger signals' associated with the implantation of the scaffolds due to tissue injury which primed the system for an enhanced immune response. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2991 / 2999
页数:9
相关论文
共 27 条
[1]
ANDERSON JM, 1993, CARDIOVASC PATHOL, V2, pS33
[2]
Host response to tissue engineered devices [J].
Babensee, JE ;
Anderson, JM ;
McIntire, LV ;
Mikos, AG .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 33 (1-2) :111-139
[3]
Viability of HEMA-MMA microencapsulated model hepatoma cells in rats and the host response [J].
Babensee, JE ;
Sefton, MV .
TISSUE ENGINEERING, 2000, 6 (02) :165-182
[4]
Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses [J].
Beg, AA .
TRENDS IN IMMUNOLOGY, 2002, 23 (11) :509-512
[5]
Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells [J].
Cella, M ;
Engering, A ;
Pinet, V ;
Pieters, J ;
Lanzavecchia, A .
NATURE, 1997, 388 (6644) :782-787
[6]
Natural adjuvants: Endogenous activators of dendritic cells [J].
Gallucci, S ;
Lolkema, M ;
Matzinger, P .
NATURE MEDICINE, 1999, 5 (11) :1249-1255
[7]
Danger signals: SOS to the immune system [J].
Gallucci, S ;
Matzinger, P .
CURRENT OPINION IN IMMUNOLOGY, 2001, 13 (01) :114-119
[8]
NF-κB and rel proteins:: Evolutionarily conserved mediators of immune responses [J].
Ghosh, S ;
May, MJ ;
Kopp, EB .
ANNUAL REVIEW OF IMMUNOLOGY, 1998, 16 :225-260
[9]
Ishaug SL, 1997, J BIOMED MATER RES, V36, P17
[10]
CD4+ T cell mediated destruction of xenografts within cell-impermeable membranes in the absence of CD8(+) T cells and B cells [J].
Loudovaris, T ;
Mandel, TE ;
Charlton, B .
TRANSPLANTATION, 1996, 61 (12) :1678-1684